Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Inhibrx Q4 2023 GAAP EPS $(1.73) Misses $(1.04) Estimate, Sales $1.63M Beat $50.00K Estimate

Author: Benzinga Newsdesk | February 28, 2024 10:21am
Inhibrx (NASDAQ:INBX) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.04) by 66.35 percent. The company reported quarterly sales of $1.63 million which beat the analyst consensus estimate of $50.00 thousand by 3.17K percent. This is a 496.35 percent increase over sales of $274.00 thousand the same period last year.

Posted In: INBX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist